AGAmanda de Farias Gabriel

Amanda de Farias Gabriel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amanda de Farias Gabriel has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Photobiomodulation in the management of oral lesions: a targeted, evidence-based approach

    by Valesca Sander Koth, Amanda de Farias Gabriel, Iohanna Deckmann, Rogerio Moraes Castilho, Felipe Nor, Marcelo Lazzaron Lamers, José Antonio Poli de Figueiredo, Manoela Domingues Martins

    This review synthesizes current literature on laser applications in dentistry, with particular emphasis on the biological mechanisms of photobiomodulation (PBM), dosimetric considerations, tissue interactions, and the clinical management of the most prevalent oral lesions. The oral disorders most frequently investigated for the therapeutic use of PBM were: a) oral pain conditions: trigeminal neuralgia, temporomandibular disorders, and burning mouth syndrome; b) oncology-related conditions: oral mucositis and hyposalivation; c) immune-mediated disorders: recurrent aphthous stomatitis and oral lichen planus; and d) viral infections: herpes labialis. A wide range of laser parameters has shown clinical benefits in the treatment of these disorders. These outcomes are attributed to the anti-inflammatory, analgesic, and tissue repair effects of PBM, which may occur immediately and cumulatively over repeated sessions. PBM therapy is a valuable therapeutic resource in contemporary dentistry and may be successfully applied in a wide range of clinical conditions. Clinical effectiveness of PBM depends on appropriate dosimetry and irradiation parameters according to the biological characteristics of each condition and therapeutic target. Therefore further well-designed randomized clinical trials and protocol standardization are still required to strengthen clinical recommendations and optimize reproducibility.


  • Development and Evaluation of a Convolutional Neural Network for Microscopic Diagnosis Between Pleomorphic Adenoma and Carcinoma Ex‐Pleomorphic Adenoma

    by Sebastião Silvério Sousa‐Neto, Thaís Cerqueira Reis Nakamura, Daniela Giraldo‐Roldan, Giovanna Calabrese dos Santos, Felipe Paiva Fonseca, Cinthia Verónica Bardález López de Cáceres, Ana Lúcia Carrinho Ayroza Rangel, Marco Antonio Trevizani Martins, Amanda De Farias Gabriel, Virgilio Gonzales Zanella, et al.

    Aims: To develop a model capable of distinguishing carcinoma ex‐pleomorphic adenoma from pleomorphic adenoma using a convolutional neural network architecture.Methods and Results: A cohort of 83 Brazilian patients, divided into carcinoma ex‐pleomorphic adenoma (n = 42) and pleomorphic adenoma (n = 41), was used for training a convolutional neural network. The whole‐slide images were annotated and fragmented into 743 869 (carcinoma ex‐pleomorphic adenomas) and 211 714 (pleomorphic adenomas) patches, measuring 224 × 224 pixels. Training (80%), validation (10%), and test (10%) subsets were established. The Residual Neural Network (ResNet)‐50 was chosen for its recognition and classification capabilities. The training and validation graphs, and parameters derived from the confusion matrix, were evaluated. The loss curve recorded 0.63, and the accuracy reached 0.93. Evaluated parameters included specificity (0.88), sensitivity (0.94), precision (0.96), F1 score (0.95), and area under the curve (0.97).Conclusions: The study underscores the potential of ResNet‐50 in the microscopic diagnosis of carcinoma ex‐pleomorphic adenoma. The developed model demonstrated strong learning potential, but exhibited partial limitations in generalization, as indicated by the validation curve. In summary, the study established a promising baseline despite limitations in model generalization. This indicates the need to refine methodologies, investigate new models, incorporate larger datasets, and encourage inter‐institutional collaboration for comprehensive studies in salivary gland tumors.


  • Oral mucositis assessment in pediatric and adolescent oncological patients: A systematic review

    by Júlia Breda Soares, Amanda de Farias Gabriel, Laura Borges Kirschnick, Vinicius Coelho Carrard, Marina Curra, Lauren Frenzel Schuch, Marco Antonio Trevizani Martins

    Oral mucositis (OM) is a prevalent acute adverse effect of various cancer treatments. Accurate assessment of OM is vital for effective prevention and treatment strategies. However, a lack of validated pediatric instruments for evaluating OM can lead to unreliable data, and hinder interventional and epidemiological research. This study aims to evaluate the methods used for assessing OM in pediatric oncology patients. A systematic review of four databases and a manual search yielded 113 articles. Nine different scales were identified, with the World Health Organization (WHO) scale being the most commonly used (61.9%). The Children's International Mucositis Evaluation Scale (ChIMES) was used in 7.9% of the studies. Of the 8155 pediatric patients evaluated, 47.7% had both hematological malignancies and malignant solid tumors, while 46% had solely hematological malignancies. Despite the prevalence of the WHO scale, it lacks pediatric‐specific criteria. Future OM research should incorporate validated tools like ChIMES for improved pediatric assessment.


  • Open Access

    Cistos e tumores odontogênicos: estudo retrospectivo dos casos diagnosticados no período de 10 anos em um hospital no sul do Brasil

    by Bruna Luísa Neumann, Stéfanie Thieme, Amanda De Farias Gabriel, Virgilio Gonzales Zanella, Felipe Martins Silveira, Ricardo Gallicchio Kroef, Marinez Bizarro Barra, Marco Antonio Trevizani Martins

    Introduction: odontogenic lesions (OLs) represent a heterogeneous group of oral and maxillofacial pathologies presenting distinct characteristics. The present study aimed to identify the clinical and pathological characteristics of OLs diagnosed in a southern Brazilian hospital. Materials and methods: a retrospective study was performed to evaluate cases with histopathological diagnosis of OLs identified in the period between 2007 and 2017. The patient's medical records were evaluated in order to obtain the clinical and pathological characteristics and the histopathological diagnosis from each case. Results: a total of 255 cases of OLs were identified. From these, 197 (77%) odontogenic cysts and 58 (23%) odontogenic tumors were surveyed, with only one case (0,39%) of a malignant odontogenic neoplasm. The most prevalent diagnosis were radicular cyst (32.5%) and dentigerous cyst (31.76%), followed by odontogenic keratocyst (10.98%), odontoma (10%) and ameloblastoma (10%). The majority of the cases affected the mandible (53.7%) with a slight preference by female individuals (51%). The mean age was 34±20.53 years old. Discussion: the presented data are in accordance with the literature regarding the rarity of the diagnosis of odontogenic tumors. Conclusion: the present study demonstrated the main clinical and pathological characteristics of OLs diagnosed in a southern Brazilian hospital, contributing to a better understanding of these injuries profiles.


  • Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy

    by Marina Curra, Amanda F. Gabriel, Maria Beatriz C. Ferreira, Marco Antonio T. Martins, André T. Brunetto, Lauro J. Gregianin, Manoela Domingues Martins

    Purpose To investigate the incidence and risk factors for oral mucositis (OM) in patients with childhood cancer undergoing chemotherapy. Methods Eight hundred and twenty-nine cycles of chemotherapy were evaluated in 112 patients with childhood cancer undergoing chemotherapy. Chemotherapy protocol, hematological, hepatic, and renal function parameters were collected and compared to presence and severity of OM, as graded by the World Health Organization (WHO) scale. Patients received counseling on oral hygiene and those who presented with OM (grade ≥1) received photobiomodulation therapy (PBMT). Results Age ranged from 0 to 17 years (mean/SD, 8.58 ± 5.05) and fifty-one patients (45.54%) were females. The most common baseline diseases were leukemia (51%) followed by sarcomas (23%) and lymphomas (18%). Eight hundred and twenty-nine cycles of chemotherapy were evaluated, and OM was diagnosed in 527 cycles (63.57%). Higher incidence and severity of OM was observed in protocols using high-dose methotrexate (MTX-HD), MTX-HD cyclophosphamide/doxorubicin combination, and MTX-HD combined with cyclophosphamide (p p = 0.003), hemoglobin (p = 0.005), platelets (p = 0.034), and higher levels of total bilirubin (p = 0.027), alanine aminotransferase (ALT) (p = 0.001), and creatinine (p = 0.007). Conclusion The study contributes to the elucidation of the risk factors for OM in pediatric cancer patients. Chemotherapy protocols using MTX-HD, MTX-HD associated with doxorubicin and cyclophosphamide, and MTX-HD and cyclophosphamide a have higher incidence of severe grades of OM. Other toxicities such as hematological, hepatic, and renal also developed in patients with OM.


  • Risk factors associated with the development of oral mucositis in pediatric oncology patients: Systematic review and meta‐analysis

    by Amanda de Farias Gabriel, Felipe Martins Silveira, Marina Curra, Lauren Frenzel Schuch, Vivian Petersen Wagner, Marco Antonio Trevizani Martins, Ursula da Silveira Matte, Marina Siebert, Mariana Rodrigues Botton, André Tesainer Brunetto, et al.

    Objectives: Oral mucositis (OM) is an acute toxicity related to cancer treatment. This systematic review aimed to identify potential risk factors associated with the development of OM in pediatric cancer patients.Methods: A search was performed in four electronic databases to identify studies that analyzed risk factors for OM in pediatric cancer patients.Results: Nineteen articles were included. The incidence of OM ranged from 20% to 80.4%. Chemotherapeutic agents were potential risk factors for OM in eight (42%) studies. Hematological, hepatic, and renal parameters were also considered in eight (42%) studies, while specific individual factors were reported in five (26.3%) studies. Baseline disease, oral microbiota, genetic profile, and biomarkers were reported in four (21.5%) studies each. Meta‐analysis showed that groups submitted to high‐risk chemotherapy for OM had a 2.79‐fold increased risk of OM.Conclusions: Identifying risk factors for OM is essential in order to allow individualized and early prevention treatment.


  • Oral mucositis in childhood cancer patients receiving high‐dose methotrexate: Prevalence, relationship with other toxicities and methotrexate elimination

    by Jéssica Berté Valer, Marina Curra, Amanda de Farias Gabriel, Tuany Rafaeli Schmidt, Maria Beatriz Cardoso Ferreira, Rafael Roesler, Junior Mario Correa Evangelista, Marco Antonio Trevizani Martins, Lauro Gregianin

    Background: Oral mucositis (OM) is one of the main adverse effects of the chemotherapeutic agent methotrexate (MTX).Aim: To evaluate the relationship of OM with MTX metabolism time and other toxicities in childhood, cancer patients receiving high‐dose of methotrexate (HD‐MTX).Design: Seventy‐seven childhood patients receiving HD‐MTX for treatment of leukaemia, osteosarcoma or lymphoma were evaluated. MTX serum level, hepatic and renal function parameters, and presence and intensity of OM were analysed.Results: The patients were submitted to 255 cycles of chemotherapy. OM was diagnosed in 191 (74.9%) cycles. Of these, 119 (46.6%) presented ulcerative lesions. Lymphoma was associated with severe OM (P = .01). OM was associated with higher serum levels of aspartate aminotransferase (P = .006), alanine aminotransferase (P = .04) and creatinine (P = .008). Increase of one unit of total bilirubin and indirect bilirubin associated, respectively, with 11% and 39% higher prevalence of OM. For each increase of one unit of creatinine serum level, it was observed a 37% higher prevalence of OM in patients with lymphoma. No association was found between delayed excretion of MTX and OM development.Conclusions: OM is a prevalent complication of childhood cancer patients receiving HD‐MTX. Renal and hepatic toxicity could be considered risk factors for OM, especially in patients with lymphoma.